サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1629250

神経芽腫治療薬の世界市場：投与経路別・種類別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年～2032年)

Neuroblastoma Drugs Market, By Route of Administration, By Type, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
神経芽腫治療薬の世界市場：投与経路別・種類別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年～2032年)
出版日: 2024年12月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

神経芽腫治療薬の市場規模は2023年に8億1,550万米ドルとなり、2024年から2032年にかけてCAGR 5.80%で拡大

神経芽腫治療薬の市場力学

神経芽腫発生率の上昇

神経芽腫治療薬の市場拡大を促進する主な要因の1つは、この疾患の発生率の上昇です。神経芽腫の診断は近年、特に若年層で顕著に増加しています。この発生動向の結果、洗練された成功する治療戦略の必要性が高まっています。製薬企業や研究者は、診断能力の強化や認知度の向上により、より多くの症例が発見されるにつれて、新規の神経芽腫治療薬の創製に向けた取り組みを強化することが奨励されており、これが神経芽腫治療薬市場の拡大を支えています。

神経芽腫治療薬市場：主な考察

当社のリサーチアナリストが共有した分析によると、世界の神経芽腫治療薬市場は予測期間 (2024-2032年) に約5.80%のCAGRで年間成長すると推定されます。

投与経路別に見ると、注入剤のカテゴリーが2023年に最大の市場シェアを示すと予測されました。

エンドユーザー別に見ると、2023年には病院が主要セグメントでした。

地域別では、北米が2023年の主要収益源でした。

神経芽腫治療薬市場：セグメンテーション分析

神経芽腫治療薬の世界市場は、投与経路、種類、エンドユーザー、地域に基づいてセグメント化されます。

投与経路に基づき、神経芽腫治療薬市場は経口剤と注入剤に分別されます。2023年、注入剤は、その有効性、簡便性、正確な量の神経芽腫用医薬品を投与する能力により、世界の神経芽腫用医薬品市場において支配的な地位を占めています。このカテゴリーの成長をさらに後押ししているのが注入剤であり、これは信頼性が高く簡便な投与経路を提供し、迅速な吸収と生物学的利用能を保証します。

種類別では、化学療法、免疫療法、骨髄移植、レチノイド療法、手術、その他に分類されます。知識と研究開発の進展により、免疫療法はより持続的で効果的な結果が期待されており、神経芽腫治療薬市場の予測期間中に最も高い年間平均成長率 (CAGR) を記録すると予測されています。免疫療法は現在、世界最大の市場シェアを占めています。さらに、このセグメントは、免疫療法の勢いを強化し、変化する神経芽腫治療分野におけるゲームチェンジ戦略として確立するための継続的な臨床試験と協力的な取り組みの結果として成長しています。

神経芽腫治療薬市場：地域別分析

地理的には、神経芽腫治療薬市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

北米は2023年に神経芽腫治療薬の最大の市場シェアを占めました。この増加は、神経芽腫症例の増加と技術的に進歩した医薬品の開発の両方によるものです。推定によると、米国は2015年に1,900億米ドル以上をがん治療に費やしており、この金額は2020年には2,000億米ドル以上に増加すると予想されています。さらに、神経芽腫治療薬市場は、医療部門の支出の増加と神経芽腫治療用の希少疾病用医薬品の承認により拡大しています。神経芽腫の合併症を予防するために化学療法や薬物療法を受ける人が増えるにつれて、神経芽腫市場は拡大すると予想されます。

欧州の神経芽腫治療薬市場は第2位のシェアを占めると予想されています。小児がんの罹患率の上昇とがん治療費の高騰が市場拡大の主な要因です。さらに、部位特異的な活性と体への細胞毒性作用がないことから、神経芽腫の治療薬として初めてライセンシングされた抗GD2薬は大きな需要が見込まれています。さらに、この地域の乳幼児人口の増加と神経芽腫に対する最先端で革新的な治療法の創出が、神経芽腫治療薬市場の拡大を後押ししています。さらに、神経芽腫の診断と治療に関する知識が深まったことで、細胞媒介免疫療法を用いた抗がん剤開発のための新規腫瘍ターゲットに集中することが可能になった。

神経芽腫治療薬市場：競合情勢

Y-mabs Therapeutics, Inc.、Bristol-Myers Squibb Company、MacroGenics Inc.、AstraZeneca plc、Eli Lilly and Companyなど、世界規模および地域規模で事業を展開するさまざまな競合企業の存在が、神経芽腫治療薬市場の断片化を高めている主な要因です。それぞれが市場全体の力学に貢献する幅広い事業が競合情勢を定義しています。既存の業界大手、新規参入企業、専門的ソリューションを提供する企業間の市場シェア争いが、この細分化の原因です。神経芽腫治療薬市場では、大手企業が買収、提携、契約、製品承認を製品ポートフォリオを拡大するための重要な開発戦術として利用しています。例えば、商業段階のバイオ医薬品事業を展開するY-mAbs Therapeutics, Inc.によると、2023年5月、ブラジル保健規制庁はDANYELZA (naxitamab-gqgk) 40mg/10mL注入剤の商業化を承認しました。ブラジルでは、Y-mAbs社のパートナーであるAdium Pharma S.A.がDANYELZAを販売します。

目次

第1章 神経芽腫治療薬市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 神経芽腫治療薬の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 神経芽腫治療薬市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 神経芽腫治療薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 神経芽腫治療薬の市場情勢

  • 神経芽腫治療薬の市場シェア分析 (2023年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 神経芽腫治療薬市場：投与経路別

  • 概要
    • セグメント別シェア分析：投与経路別
    • 経口剤
    • 注入剤

第8章 神経芽腫治療薬市場：種類別

  • 概要
    • セグメント別シェア分析：種類別
    • 化学療法
    • 免疫療法
    • 骨髄移植
    • レチノイド療法
    • 手術
    • その他

第9章 神経芽腫治療薬市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 病院
    • 在宅医療
    • 専門クリニック
    • その他

第10章 神経芽腫治療薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋 (APAC)
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 韓国
    • 日本
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：神経芽腫治療薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Y-mabs Therapeutics, Inc.
    • Bristol-Myers Squibb Company
    • MacroGenics Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • Recordati Group
    • Cellectar Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • United Therapeutics Corporation
    • Others

第12章 AnalystViewの全方位的分析

目次
Product Code: ANV4423

REPORT HIGHLIGHT

Neuroblastoma Drugs Market size was valued at USD 815.5 Million in 2023, expanding at a CAGR of 5.80% from 2024 to 2032.

The most prevalent kind of cancer among newborns is neuroblastoma. The sympathetic nervous system's embryonic malignancy, which arises from the neuroblasts, is what causes the cancer. The malignancy spreads to the spinal cord, chest, or adrenal nerve tissues. Neuroblastoma is diagnosed before the age of five in over 90% of cases. In rare instances, prenatal ultrasounds may reveal the malignancy. The increased incidence of neuroblastoma and childhood cancer are the main causes of the neuroblastoma drug market's expansion. According to estimates, as of 2023, over 700 children in the US will receive a neuroblastoma diagnosis annually. Additionally, the neuroblastoma drugs market is expected to develop as a result of people's increased awareness of cancer diagnosis and treatment. In the upcoming years, it is anticipated that the growing number of incident instances that are age- and gender-specific will spur industry expansion.

Neuroblastoma Drugs Market- Market Dynamics

Rising Incidence of Neuroblastoma

One of the main driver driving the market expansion for neuroblastoma drugs is the rise in the disease's occurrence. Neuroblastoma diagnoses have increased noticeably in recent years, especially in juvenile populations. The need for sophisticated and successful therapeutic strategies has increased as a result of this incidence trend. Pharmaceutical firms and researchers are encouraged to step up their efforts in creating novel neuroblastoma medications as more cases are discovered due to enhanced diagnostic capabilities and more awareness, which supports the neuroblastoma drug market's expansion.

Neuroblastoma Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global Neuroblastoma Drugs Market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2024-2032)

Based on the route of administration segmentation, the injectable category was predicted to show maximum market share in the year 2023

Based on end-user segmentation, the hospitals were the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroblastoma Drugs Market- Segmentation Analysis:

The Global Neuroblastoma Drugs Market is segmented on the basis of Route of Administration, Type, End-user, and Region.

Based on the route of administration, the neuroblastoma drugs market is segregated into Oral and Injectable. In 2023, the injectable category held a dominant market position in the worldwide neuroblastoma drugs market due to its effectiveness, ease, and capacity to administer precise amounts of neuroblastoma pharmaceuticals. Further bolstering the category growth are injectable formulations, which provide a dependable and straightforward administration route, guaranteeing quick absorption and bioavailability-particularly important in pediatric oncology.

By type, the market is divided into Chemotherapy, Immunotherapy, Bone Marrow Transplantation, Retinoid therapy, Surgery, and Others. Due to growing knowledge and research developments, immunotherapy shows promise for more lasting and effective results, and it is anticipated to record the highest compound annual growth rate (CAGR) during the neuroblastoma drugs market forecast period. Immunotherapy currently holds the largest market share worldwide. Furthermore, the segment is growing as a result of continuous clinical trials and cooperative efforts that strengthen immunotherapy's momentum and establish it as a game-changing strategy in the changing field of neuroblastoma treatment.

Neuroblastoma Drugs Market- Geographical Insights

Geographically, the Neuroblastoma Drugs Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

North America held the greatest market share for neuroblastoma drugs in 2023. This increase is ascribed to both the rise of neuroblastoma cases and the development of technologically advanced medications. According to estimates, the United States spent more than USD 190 billion on cancer treatment in 2015, and that amount is expected to rise to over USD 200 billion in 2020. Additionally, the neuroblastoma drugs market is expanding due to rising healthcare sector spending and the approval of orphan drugs for the neuroblastoma treatment. The industry is expected to rise as more people receive chemotherapy and medication therapies to prevent more complications from the illness.

The market for neuroblastoma drugs in Europe is anticipated to hold the second-largest share. The rising incidence of childhood cancer and rising cancer treatment costs are the main factors driving the market's expansion. Additionally, due to its site-specific activity and lack of cytotoxic effects on the body, anti-GD2, the first medication licensed for the treatment of neuroblastoma, is seeing tremendous demand. Furthermore, the region's growing infant population and the creation of cutting-edge, innovative treatments for neuroblastoma are driving the neuroblastoma drugs market expansion. In addition, greater knowledge about neuroblastoma diagnosis and treatment has made it possible to concentrate on novel tumour targets for the development of cancer medications using cell-mediated immunotherapy.

Neuroblastoma Drugs Market- Competitive Landscape:

The presence of various competitors operating on a worldwide and regional scale, such as Y-mabs Therapeutics, Inc., Bristol-Myers Squibb Company, MacroGenics Inc., AstraZeneca plc, Eli Lilly and Company, and others are the main reason for the high degree of fragmentation in the neuroblastoma drugs market. A wide range of businesses that each contribute to the overall dynamics of the market defines the competitive landscape. The competition for market share among existing industry giants, newcomers, and specialist solution providers is the cause of this fragmentation. The market for neuroblastoma drugs has seen major players use acquisition, collaboration, agreement, and product approval as important developmental tactics to expand their product portfolio. For instance, in May 2023, The Brazilian Health Regulatory Agency approved the commercialization of DANYELZA (naxitamab-gqgk) 40mg/10mL injection, according to Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical business. In Brazil, Adium Pharma S.A., a partner of Y-mAbs, will sell DANYELZA.

Recent Developments:

February 2023: The European Medicines Agency approved the proposed pediatric investigation plan for naxitamab, according to a statement released by commercial-stage biopharmaceutical startup Y-mAbs Therapeutics, Inc. The Pediatric Committee expressed a favourable judgment, which led to the conclusion. The indication addressed by the PIP, relapsed/refractory high-risk neuroblastoma, as well as osteosarcoma, are the conditions for which Y-mAbs is developing naxitamab.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROBLASTOMA DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Y-mabs Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • MacroGenics Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Recordati Group
  • Cellectar Biosciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • United Therapeutics Corporation
  • Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Immunotherapy
  • Bone Marrow Transplantation
  • Retinoid therapy
  • Surgery
  • Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Speciality Clinics
  • Other

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroblastoma Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroblastoma Drugs Market Snippet by Route of Administration
    • 2.1.2. Neuroblastoma Drugs Market Snippet by Type
    • 2.1.3. Neuroblastoma Drugs Market Snippet by End-user
    • 2.1.4. Neuroblastoma Drugs Market Snippet by Country
    • 2.1.5. Neuroblastoma Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroblastoma Drugs Key Market Trends

  • 3.1. Neuroblastoma Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroblastoma Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroblastoma Drugs Market Opportunities
  • 3.4. Neuroblastoma Drugs Market Future Trends

4. Neuroblastoma Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroblastoma Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neuroblastoma Drugs Market Landscape

  • 6.1. Neuroblastoma Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroblastoma Drugs Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 7.1.2. Oral
    • 7.1.3. Injectable

8. Neuroblastoma Drugs Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Immunotherapy
    • 8.1.4. Bone Marrow Transplantation
    • 8.1.5. Retinoid therapy
    • 8.1.6. Surgery
    • 8.1.7. Others

9. Neuroblastoma Drugs Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Homecare
    • 9.1.4. Speciality Clinics
    • 9.1.5. Others

10. Neuroblastoma Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Neuroblastoma Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Neuroblastoma Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Neuroblastoma Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Neuroblastoma Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Neuroblastoma Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Neuroblastoma Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Y-mabs Therapeutics, Inc.
    • 11.2.2. Bristol-Myers Squibb Company
    • 11.2.3. MacroGenics Inc.
    • 11.2.4. AstraZeneca plc
    • 11.2.5. Eli Lilly and Company
    • 11.2.6. Recordati Group
    • 11.2.7. Cellectar Biosciences, Inc.
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Pfizer Inc.
    • 11.2.10. United Therapeutics Corporation
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us